SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Health Canada Approves Lilly’s Mounjaro to Reduce Cardiovascular Risk

Health Canada approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. The supplied body says it is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack and stroke risk.

Related stories